Medical gas safety: the new chapter

After 20 years, HTM 02-01 has changed. The 2026 revision is much more than an update of technical references or a replacement for an ageing document. Parts A and B together establish a stronger lifecycle approach to Medical Gas Pipeline Systems (MGPS), linking the way systems are conceived and designed with the way they are validated, handed over, operated, maintained, modified, and governed.

The underlying engineering principles remain familiar: the supply must be adequate, correctly identified, continuous, and of the required medicinal quality. What has changed is the context in which those principles are applied. Clinical practice has evolved, oxygen demand has changed, healthcare estates have become more complex, sustainability is a strategic requirement, and the COVID-19 pandemic demonstrated that installed capacity does not always translate into usable resilience at the patient. At the same time, experience has shown the limitations of treating medical gases primarily as an Estates engineering service rather than as a safety-critical clinical, pharmaceutical, and engineering system.

The new HTM therefore asks organisations to make decisions using better evidence and stronger governance. Design should start with clinical need and risk. Resilience should consider the complete route from source to patient. Validation and verification should demonstrate that the installed system actually delivers the design intent. Operational management should make risks visible to the organisation, while competence, pharmacy input, and clinical engagement should be built into the assurance process rather than added at the end.